Phase4 Partners
4th Floor, One Cavendish Place, London, England, W1G 0QF, United Kingdom
Overview
Long known as one of the leading life science venture capital firms based in Europe, Phase4 Partners, formerly known as Phase4 Ventures, has more recently expanded its mission to include a range of innovative investment vehicles to meet the needs of major pharmaceutical companies as well as sophisticated private and institutional investors from around the world. Founded in 1999 with its home office in London, Phase4 has invested over $400 million in 24 companies in both Europe and the US, including such notable successes as Pharmion, Arakis, Proteolix, Albireo, and OncoMed (NASDAQ: OMED). Phase4 is particularly proud of its key role in funding the development of breakthrough products such as Kyprolis (acquired by Onyx when it purchased Proteolix); Ultibro Breezhaler (a Novartis product originally developed by Arakis); and Vidaza and Thalomid (both acquired by Celgene when it purchased Pharmion); as well as important advances now in clinical trials including OncoMed’s line of innovative products directed at blocking cancer stem cells and Albireo’s elobixibat, now in Phase III studies being conducted by Albireo’s partner Ferring. All of these products offer significant improvements in the treatment of serious diseases while having the potential to generate large profits for the companies involved as well as our investors. Phase4 is a member of the British Private Equity and Venture Capital Association (BVCA), and the European Private Equity and Venture Capital Association (EVCA).
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Nabriva Therapeutics
Participated · Series B · Apr 2015
Nabriva Therapeutics AG is a Vienna- and Philadelphia-based biotechnology company focused on the discovery and development of pleuromutilin antibiotics. Its lead product, lefamulin (BC‑3781), is the first systemically available pleuromutilin for human use and is entering pivotal phase 3 studies for community-acquired bacterial pneumonia (CABP). Lefamulin shows in vitro activity against the most common CABP pathogens, including S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, M. pneumoniae, L. pneumophila and C. pneumoniae, including multi-drug resistant strains. Preclinical programs include Extended Spectrum Pleuromutilins (ESPs), a new generation targeting CDC‑identified urgent and serious threats such as carbapenem-resistant Enterobacteriaceae (CRE). The company is led by CEO Dr Colin Broom. Nabriva completed a $120M Series B financing, with an initial $50M tranche to advance lefamulin into phase 3 studies and to continue pipeline development. Nabriva Therapeutics is a Vienna, Austria–based biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens. Its core program is a systemic pleuromutilin antibiotic program. The company plans to use funds to advance that program up to and including the generation of phase II efficacy data in the second half of 2010. Nabriva closed a €15M equity financing from existing investors to support development. The financing extends the company's cash reach into 2011, according to CEO Dr. David Chiswell. Since its foundation in 2006 the company has raised €57.4M (approximately $84M) in total equity funding.
Team
No current team members are available.